These data showed that treatment with a PI3K inhibitor plus dexamethasone can ameliorate GC sensitivity in severe asthma in vitro via a mechanism involving the restoration of HDAC2 activity and inhibition of phosphorylation of nuclear signaling transcription factors (Fig. 8). The gene discussed is HDAC2; the disease is asthma.